Novartis’ fevipiprant hailed a “game-changer” in asthma treatment
Researchers are hailing Novartis’ fevipiprant (QAW039) as a game-changer in asthma treatment after a Lancet-published trial showed its potential to significantly reduce the severity of the condition.
Read More
